NeoImmuneTech Statistics

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 116.17 billion. The enterprise value is 98.65 billion.

Market Cap	116.17B
Enterprise Value	98.65B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

NeoImmuneTech has 98.87 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	98.87M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	0.96%
Float	93.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	632.66
PB Ratio	3.52
P/TBV Ratio	4.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.63
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.57

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.33.

Current Ratio	1.45
Quick Ratio	1.24
Debt / Equity	0.33
Debt / EBITDA	n/a
Debt / FCF	-0.29
Interest Coverage	-57.04

Financial Efficiency

Return on equity (ROE) is -75.37% and return on invested capital (ROIC) is -41.66%.

Return on Equity (ROE)	-75.37%
Return on Assets (ROA)	-34.22%
Return on Invested Capital (ROIC)	-41.66%
Return on Capital Employed (ROCE)	-107.01%
Revenue Per Employee	3.53M
Profits Per Employee	-721.84M
Employee Count	52
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-44.42M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -36.55% in the last 52 weeks. The beta is 0.97, so NeoImmuneTech's price volatility has been similar to the market average.

Beta (5Y)	0.97
52-Week Price Change	-36.55%
50-Day Moving Average	1,241.94
200-Day Moving Average	1,244.51
Relative Strength Index (RSI)	34.33
Average Volume (20 Days)	1,538,682

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 183.62 million and -37.54 billion in losses. Loss per share was -379.66.

Revenue	183.62M
Gross Profit	3.09B
Operating Income	-38.06B
Pretax Income	-37.58B
Net Income	-37.54B
EBITDA	-34.10B
EBIT	-38.06B
Loss Per Share	-379.66

Full Income Statement

Balance Sheet

The company has 28.46 billion in cash and 10.94 billion in debt, giving a net cash position of 17.52 billion or 177.25 per share.

Cash & Cash Equivalents	28.46B
Total Debt	10.94B
Net Cash	17.52B
Net Cash Per Share	177.25
Equity (Book Value)	32.97B
Book Value Per Share	333.48
Working Capital	10.37B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -36.51 billion and capital expenditures -1.84 billion, giving a free cash flow of -38.35 billion.

Operating Cash Flow	-36.51B
Capital Expenditures	-1.84B
Free Cash Flow	-38.35B
FCF Per Share	-387.91

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-20,725.74%
Pretax Margin	-20,466.31%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-32.31%
FCF Yield	-33.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1